Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab maintenance with or without pemetrexed after first-line bevacizumab + cisplatin + pemetrexed in advanced non-squamous NSCLC
2008-007008-27Phase 3Completed
- Sponsor
- Roche
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Maintenance bevacizumab + pemetrexed with Maintenance bevacizumab alone (2 arms). Primary endpoint: Progression-free survival. Started May 2009; status: completed.
02
Drugs
bevacizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-007008-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007008-27.